MannKind(MNKD) - 2025 Q1 - Quarterly Results

EXHIBIT 99.1 • Planning to advance into the next phase of global development in 2H 2025 • 1Q 2025 revenues of $78M, +18$13M, + 24% v. 1Q 2024 • 1Q 2025 non-GAAP net income of $22M, +43% v. 1Q 2024 • Advanced pipeline: • Expect to submit sBLA for Afrezza ® in pediatric patients in mid-2025 • MNKD-101: NTM global Phase 3 trial enrollment on track for interim analysis • MNKD-201: Expect to continue to next phase of global development in 2H 2025 MANNKIND CORPORATION REPORTS ...